1. Home
  2. Vol 19, No 2 (2025)
  3. Hanum

Comparison of c-MYC Expression between Patients with Germinal Center and Non-Germinal Center B-cell-like Diffuse Large B Cell Lymphoma

Sitti Fatimah Hanum, Endang Sri Roostini Hardjolukito, Kusmardi Kusmardi, Farida Murtiani, Aninda Dinar Widiantari, Vivi Setiawaty

Abstract


Background: c-MYC expression has been used as a prognostic marker to predict prognosis and determine therapeutic strategies in both Diffuse Large B Cell Lymphoma (DLBCL) subtypes. No study on c-MYC expression associated with DLBCL has ever been conducted in Indonesia. Our study aimed to evaluate differences in c-MYC expression in both DLBCL subtypes and assess the immunophenotype profile.

Method: We selected 40 DLBCL cases and divided them into Germinal Center B-cell (GCB) and non-GCB subtypes using Hans Criteria. We evaluated c-MYC expression, and a cut-off value of 60.4% was determined using Receiver Operating Characteristic (ROC) curve analysis.

Results: We found that c-MYC expression was significantly higher in GCB subtypes compared to non-GCB subtypes (n = 17 (42.5%) vs n = 20 (7.5%), p < 0.000 and mostly had an immunophenotype of CD10+/BCL6+/MUM1+.

Conclusion: Higher c-MYC expression is found more frequently in GCB subtypes. These findings suggest that c-MYC may play a subtype-specific role in DLBCL pathogenesis, potentially influencing therapeutic decisions for Indonesian patients. Future studies should validate these results in larger, multi-center cohorts and explore the mechanistic link between c-MYC and the GCB subtype and its clinical implications for targeted therapies.


Keywords


c-MYC, diffuse large B-cell lymphoma (DLBCL), germinal center B cell-like (GCB)

Full Text: View | Download

DOI: 10.33371/ijoc.v19i2.1277

Article Metrics

Abstract View: 454,
PDF Download: 95
             

References


Martelli M, Ferreri AJM, Agostinelli C, et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87:146–71.

Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000;95:2084–92.

Nowakowski GS, Czuczman MS. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection? Am Soc Clin Oncol Educ Book. 2015:e449-57.

Alizadeh AA, Eisen MB, Eisen MB, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.

Quintanilla-Martinez L. Is it only about MYC? How to approach the diagnosis of diffuse large B-cell lymphomas. Hematol Oncol. 2015;33 Suppl 1:50–5.

Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122:3884–91.

Karube K, Campo E. MYC Alterations in Diffuse Large B-Cell Lymphomas. Semin Hematol. 2015;52:97–106.

Zhou M, Wang J, Ouyang J, et al. MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy. Tumor Biology. 2014;35:6757–62.

Cai Q, Medeiros LJ, Xu X, Young KH. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget. 2015;6.

Dominguez-Sola D, Victora GD, Ying CY, et al. The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol. 2012;13:1083–91.

Hoeller S, Tzankov A, Stenner F, Dirnhofer S. When and how to test for C-MYC in aggressive B cell lymphomas. J Hematop. 2015;8:13–20.

Aukema SM, Kreuz M, Kohler CW, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99:726–35.

Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.

Cattoretti G. MYC expression and distribution in normal mature lymphoid cells. J Pathol. 2013;229:430–40.

Kluk MJ, Ho C, Yu H, et al. MYC immunohistochemistry to identify MYC-driven B-cell lymphomas in clinical practice. Am J Clin Pathol. 2016;145:166–79.

Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology 2018;50:74–87.

Perry AM, Mitrovic Z, Chan WC. Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control. 2012;19:214–26.

Choi WWL, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clinical Cancer Research. 2009;15:5494–502.

Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol. 2015;15:172–84.

De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol. 2015;15:137–48.

Nussenzweig A, Nussenzweig MC. Origin of chromosomal translocations in lymphoid cancer. Cell. 2010;141:27–38.

Tsuboi K, Iida S, Inagaki H, Kato M, Hayami Y, Hanamura I, et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia. 2000;14:449–56.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.